Trial in progress: A phase I study of AMG 199, a half-life extended   bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in   patients with gastric and gastroesophageal junction (G/GEJ) cancer.

Dokumenttyp:: Meeting Abstract
Autor(en):: Chao, Joseph; Buxo, Elvira; Cervantes, Andres; Dayyani, Farshid; Rocha Lima, Caio Max Sao Pedro; Greil, Richard; Van Laarhoven, Hanneke W. M.; Lorenzen, Sylvie; Heinemann, Volker; Kischel, Roman; Shitara, Kohei; Lordick, Florian
Titel:: Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2020
Band / Volume:: 38 Suppl S
Heft / Issue:: 15
Print-ISSN:: 0732-183X
TUM Einrichtung:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Vorkommen: